Using FDA Law to Threaten Medical Practice

New England Journal of Medicine 2026

View at publisher
Authors: Lewis A. Grossman, Nathan G. Cortez, Patricia J. Zettler
DOI: 10.1056/nejmp2516086
Cited by: 0

Abstract

Though recent subpoenas from the U.S. DOJ target providers of gender-affirming care, the legal arguments behind them could affect physicians prescribing off-label treatment for any reason.

Fields of Study & Subjects

Pharmaceutical industry and healthcare Biomedical Ethics and Regulation Pharmaceutical Economics and Policy

Publication details

Journal / source
New England Journal of Medicine
Volume
394
Issue
6
Pages
524–525
Publication date
7 January 2026
Language
EN